CRISPR Therapeutics Earnings
NASDAQ: CRSPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
53.39+2.95 (+5.85%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CRISPR Therapeutics earnings summary
In its most recent report on Aug 3, 2026 (Q2 2026), CRSP posted EPS of $-0.94. Revenue for the quarter was $10.2 million. Across the last 16 reports, CRSP shares moved an average of 7.2% (in either direction) in the first trading session after results, rising 9 times and falling 7 times.
Summary generated from market data by MetaCap's automated system. Methodology
CRSP earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 3, 2026 | — | $-0.94 | — | +0.1% |
| May 4, 2026 | — | $-1.28 | — | -11.7% |
| Feb 12, 2026 | — | $-1.32 | — | +0.7% |
| Nov 10, 2025 | — | $-1.17 | — | -4.4% |
| Aug 4, 2025 | — | $-2.40 | — | +8.6% |
| May 6, 2025 | — | $-1.58 | — | +8.8% |
| Feb 11, 2025 | — | $-0.41 | — | -3.6% |
| Nov 5, 2024 | — | $-1.01 | — | -8.5% |
| Aug 5, 2024 | — | $-1.49 | — | +1.8% |
| May 8, 2024 | — | $-1.43 | — | +9.9% |
| Feb 21, 2024 | — | $1.12 | — | -0.3% |
| Nov 6, 2023 | — | $-1.41 | — | +27.7% |
| Aug 7, 2023 | — | $-0.98 | — | -3.0% |
| May 8, 2023 | — | $-0.67 | — | -2.8% |
| Feb 21, 2023 | — | $-1.40 | — | +5.9% |
| Nov 1, 2022 | — | $-2.24 | — | +17.9% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.